SEPTInvestingStart Free

FULC 424B3: Acquisition

Fulcrum Therapeutics and Slate Medicines

Filed with the SEC on · accession 0001193125-26-447368

FULC filed a 424B3 (prospectus (offering)) with the SEC on Nov 4, 2026. Fulcrum Therapeutics and Slate Medicines entered into a merger agreement where Slate will become a wholly owned subsidiary of Fulcrum, with pre-Merger Slate stockholders expected to own approximately 55.9% of the combined company and Fulcrum stockholders only 5.0%. The stock moved +0.8% by the first close after the filing.

Summary of the filing

Fulcrum Therapeutics and Slate Medicines entered into a merger agreement where Slate will become a wholly owned subsidiary of Fulcrum, with pre-Merger Slate stockholders expected to own approximately 55.9% of the combined company and Fulcrum stockholders only 5.0%. The transaction includes a concurrent $245 million investment in Slate and a proposed reverse stock split of Fulcrum shares.

For details, click here →How to read a 424B3 →

Key details

Slate Concurrent Investment proceeds$245.0M
Assumed valuation of Fulcrum$31.3M
Assumed valuation of Slate (exclusive of concurrent investment)$350.0M
Estimated exchange ratio (Slate shares to Fulcrum shares)shares 25
AcquirerFulcrum Therapeutics, Inc.
TargetSlate Medicines, Inc.
Merger subsidiaryFusion Merger Sub I, Inc.
Merger subsidiaryFusion Merger Sub II, LLC

How FULC stock reacted

Close before

$3.74

Nov 3, 2026

First close after

+0.80%

$3.77

5 trading days

—

Since filing

-1.07%

$3.70

✦ Ask GOAX AI about this filing — what it means for FULC, what changed since its last filings and what to watch next.

Try it free for 7 days

🔔 Want to stay updated on new SEC filings for FULC?

Click here

Frequently asked questions

What did FULC file with the SEC on Nov 4, 2026?

FULC filed a 424B3 (Acquisition). Fulcrum Therapeutics and Slate Medicines entered into a merger agreement where Slate will become a wholly owned subsidiary of Fulcrum, with pre-Merger Slate stockholders expected to own approximately 55.9% of the combined company and Fulcrum stockholders only 5.0%. The transaction includes a concurrent $245 million investment in Slate and a proposed reverse stock split of Fulcrum shares.

What does a acquisition mean for FULC stock?

A contract important enough that investors need to know about it — a big customer contract, a loan, a merger agreement or a partnership.

How do I read a 424B3?

The final terms of an offering of shares or bonds. Look at price, number of shares and the discount to the market price. Large offerings dilute existing shareholders.

Why are SEC filings important?

Public companies must tell the SEC about anything that can change their value — results, leadership changes, big deals, new shares, bankruptcy. Filings are the official source, often before the news. A 424B3 (prospectus (offering)): The final terms of an offering of shares or bonds.

How did FULC stock react to this filing?

FULC closed at $3.74 before the filing and $3.77 on Nov 4, 2026 (+0.80%).

Other FULC SEC filings

Get alerts when FULC files with the SEC, plus live charts, key levels and news for 13,000+ stocks.

Try SEPT free for 7 days
FULC overviewFULC analysisFULC newsLatest SEC filings